Allogene Therapeutics ((ALLO)) announced an update on their ongoing clinical study.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Allogene Therapeutics is conducting a Phase 1 study titled ‘A Study to Investigate the Safety and Preliminary Efficacy of ALLO-329, an Allogeneic CAR T-cell Therapy, in Adults With Autoimmune Disease.’ The study aims to evaluate the safety, tolerability, and preliminary efficacy of ALLO-329 in treating autoimmune diseases such as systemic lupus erythematosus, idiopathic inflammatory myopathy, and systemic sclerosis. This research is significant as it explores a novel approach to managing complex autoimmune disorders.
The intervention being tested is ALLO-329, a dual anti-CD19/anti-CD70 allogeneic CAR T-cell therapy. This genetic therapy is designed to target specific proteins associated with autoimmune diseases, potentially offering a new treatment avenue for patients.
The study is interventional and follows a randomized, sequential model without masking. Its primary purpose is treatment, focusing on assessing the therapy’s safety and efficacy in a controlled setting.
The study is currently recruiting, with an estimated start date in September 2025. It was first submitted in July 2025, with the latest update also in July 2025. These dates are crucial as they mark the progression and current status of the study.
This update could influence Allogene Therapeutics’ stock performance positively, as successful results may enhance investor confidence and position the company as a leader in autoimmune therapy. Competitors in the CAR T-cell therapy space will likely monitor these developments closely.
The study is ongoing, with further details available on the ClinicalTrials portal.